CTRI/2020/09/027790尚未招募未知
Evaluation of Contraceptive Efficacy, Changes in Uterine Artery and Endometrial thickness in women using LNG IUS - CUELNG
Pregna International Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Parous and nulliparous women choosing LNG IUS for interval contraception after Cafetaria method with GATHER approach,
- •2. Willing to participate in the study
排除标准
- •1 .Known or suspected Pregnancy
- •2. Current Pelvic infection
- •3. Uterine bleeding of unknown etiology,
- •4. Post renal transplant patients
- •5. Acute liver disease or liver tumor (benign or malignant)
- •6. Known or suspected uterine or cervical neoplasia
- •7. Chorio-carcinoma patients on follow-up
- •8. Subjects at increased risk for infectious endocarditis (prosthetic heart valves, rheumatic heart disease, previous endocarditis)
- •9. Women with a prior Tubectomy/trans cervical tubal sterilization procedure (e.g., Essure)
- •10. Postmenopausal woman
- •11. Use of another hormonal contraceptive within 30 days of levonorgestrel intrauterine system placement for the study
- •12. Vaginal delivery, cesarean delivery, or abortion within six weeks prior to levonorgestrel intrauterine system insertion (uterus should be fully involuted before insertion).
- •13. Women with a uterine cavity that measures less than 6 cm or greater than 10 cm
- •14. Congenital or acquired uterine anomaly, including fibroids if they distort the uterine cavity
- •15. Acute pelvic inflammatory disease (PID) or a history of PID unless there has been a subsequent intrauterine pregnancy
- •16. Postpartum endometritis or infected abortion in the past 3 months
- •17. Known or suspected breast cancer or other progestin-sensitive cancer, now or in the past
- •18. Untreated acute cervicitis or vaginitis, including bacterial vaginosis or other lower genital tract infections
- •19. Conditions associated with increased susceptibility to pelvic infections
- •20. A previously inserted intrauterine device that has not been removed
- •21. Hypersensitivity to any component of the product
研究者
相似试验
进行中（未招募）
3 期
A 12 week prospective study of efficacy and acceptability of magnesium sulfate once weekly in adults as a management regime for constipation.Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonConstipationACTRN12609000081213Colocap Pharmaceuticals Pty Ltd100
进行中（未招募）
不适用
A study to determine the maintenance of efficacy of agomelatine (25 mg to 50 mg) to prevent relapse in out-patients with Major Depressive Disorder.A 8 to 10 weeks open period treatment with agomelatine (25 mg to 50 mg) followed by 24 weeks randomised double-blind period, placebo-controlled, parallel groups and 20 weeks of optional double-blind treatment period.MedDRA version: 3.3Level: P.T.Classification code 10025453Major Depressive DisorderEUCTR2004-003981-13-FIInstitut de Recherches Internationales Servier500
进行中（未招募）
1 期
A study to determine the maintenance of efficacy of agomelatine (25 mg to 50 mg) to prevent relapse in out-patients with Major Depressive Disorder. A 8 to 10 weeks open period treatment with agomelatine (25 mg to 50 mg) followed by 24 weeks randomised double-blind period, placebo-controlled, parallel groups and 20 weeks of optional double-blind treatment period.MedDRA version: 3.3 Level: P.T. Classification code 10025453Major Depressive DisorderEUCTR2004-003981-13-GBInstitut de Recherches Internationales Servier500
已完成
不适用
Efficacy test for evaluating the effect of "composition A" on the skin redness.Healthy peopleJPRN-UMIN000029583Kao Corporation25
已完成
不适用
A confirmation study for the improvement effect of skin quality by the test food consumptioot applicableJPRN-UMIN000037734CPCC Company Limited110